Veronica Novotny‐Diermayr

Statistics

Publications

Citations

1.3K

H-Index

Active since

2002

Affiliations

Institute of Molecular and Cell Biology(Current)

Experimental Drug Development Centre

Agency for Science, Technology and Research

National University of Singapore

National University Cancer Institute, Singapore

Veronica Novotny‐Diermayr is an author at Institute of Molecular and Cell Biology specializing in medicine, cancer pharmacology, and molecular oncology.

Publications per year

2002–2022

Publications

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

Stefan Hart, K C Goh, Veronica Novotny‐Diermayr et al. · Leukemia · 2011 · 199 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Veronica Novotny‐Diermayr, Kanda Sangthongpitag, Chang Hu et al. · Molecular Cancer Therapeutics · 2010 · 132 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

K C Goh, Veronica Novotny‐Diermayr, Stefan Hart et al. · Leukemia · 2011 · 129 citations

Medicine, Medicinal Chemistry, Oncology +11

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

Stefan Hart, K. C. Goh, Veronica Novotny‐Diermayr et al. · Blood Cancer Journal · 2011 · 109 citations · Full text

Medicine, Oncology, Pharmacology +16

A Novel Sequence in the Coiled-coil Domain of Stat3 Essential for Its Nuclear Translocation

Jing Ma, Tong Zhang, Veronica Novotny‐Diermayr et al. · Journal of Biological Chemistry · 2003 · 106 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +13

1–5 of 18